- |||||||||| Stivarga (regorafenib) / Bayer
Cost-utility analysis of sequential therapy with sorafenib followed by regorafenib versus single-line therapies in advanced hepatocellular carcinoma. (Poster Bd # E16) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_468; We evaluated the lifetime cost-effectiveness of a sequence of treatment with sorafenib followed by regorafenib (SOR-REG) compared with licensed single-line therapies for which there is no clear sequencing options available, including atezolizumab plus bevacizumab (ATEZO+BEV), which has become the standard of care in first-line treatment, as well as lenvatinib (LEN), followed by best supportive care (BSC). A sequence of SOR-REG for patients with advanced HCC is cost-effective at WTP thresholds of
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Novel GPC3-targeting radiopharmaceutical therapy for hepatocellular carcinoma. (Poster Bd # E12) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_464; A sequence of SOR-REG for patients with advanced HCC is cost-effective at WTP thresholds of Preclinical in vitro and in vivo data demonstrate the potential of RAYZ-8009 as a theranostic agent for the treatment of patients with GPC3+ HCC.
- |||||||||| Promising first-line immuno-combination therapies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis. (Poster Bd # B14) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_413;
A Markov model was built based on five global, multicenter, open-label, phase III randomized trials (Himalaya, IMbrave150, ORIENT-32, CARES-310, LEAP-002) to investigate the cost-effectiveness of tremelimumab plus durvalumab (STRIDE), atezolizumab plus bevacizumab (A+B), sintilimab plus bevacizumab biosimilar (IBI305) (S+B), camrelizumab plus rivoceranib (C+R) and pembrolizumab plus lenvatinib (P+L). As one of the promising immuno-combination therapies in the first-line systemic treatment for unresectable HCC, camrelizumab plus rivoceranib demonstrated the potential to be the most cost-effective strategy, which warranted further studies to best inform the real-world clinical practices.
- |||||||||| Tevimbra (tislelizumab-jsgr) / BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial: A prospective, open, multicenter, cohort study of neoadjuvant therapy with TACE, lenvatinib and tislelizumab versus surgical resection alone for stage A BCLC patients with single HCC larger than 5cm in diameter (EUDRACT) - Dec 5, 2023 P2, N=120, Recruiting, . .
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Preclinical, Journal: Increased c?SRC expression is involved in acquired resistance to lenvatinib in hepatocellular carcinoma. (Pubmed Central) - Nov 29, 2023 When co-administering dasatinib, a c-SRC inhibitor, the partial restoration of lenvatinib sensitivity in the JHH-7_LR cell line was observed. The present study demonstrated that increased c-SRC expression was partially associated with HCC resistance to lenvatinib, suggesting that c-SRC inhibition could reduce the resistance of HCC to lenvatinib.
- |||||||||| Journal: Aneurysm and Artery Dissection After Oral VEGFR-TKI Use in Adults With Cancer. (Pubmed Central) - Nov 29, 2023
In this study, the use of oral VEGFR-TKIs was associated with an increased risk of AAD occurrence. These findings elucidate vascular toxic effects and may provide a substantial reference for reducing the socioeconomic burden of adverse events associated with VEGFR-TKI use.
- |||||||||| Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci
Trial completion date, Trial termination, Trial primary completion date, Combination therapy: Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma (clinicaltrials.gov) - Nov 29, 2023 P1/2, N=40, Terminated, These findings elucidate vascular toxic effects and may provide a substantial reference for reducing the socioeconomic burden of adverse events associated with VEGFR-TKI use. Trial completion date: Oct 2022 --> Aug 2023 | Recruiting --> Terminated | Trial primary completion date: Jul 2022 --> Aug 2023; Enrollment is over, the study was completed
|